Yunzi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunzi Zhao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hui Hui
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China
2 shared publications - Hongzheng Wang
School of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi University, Shihezi, P. R. China
1 shared publication Hui Li
State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China
1 shared publication- Hui Li
State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University Nanjing People's Republic of China
1 shared publication - Mengyuan Zhu
Department of oncology, the seventh affiliated hospital of Sun Yat-sen University, Shenzhen, Guangdong, 510080, P.R. China
1 shared publication - Po Hu
School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Qixia District, Nanjing 210023, China
1 shared publication
Latest Publications
- 17 February 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (2) , 101-114
Multiple characteristic alterations and available therapeutic strategies of cellular senescence
Given its state of stable proliferative inhibition, cellular senescence is primarily depicted as a critical mechanism by which organisms delay the progress
- 17 February 2023
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 24 (2) , 101-114
Multiple characteristic alterations and available therapeutic strategies of cellular senescence
Given its state of stable proliferative inhibition, cellular senescence is primarily depicted as a critical mechanism by which organisms delay the progress
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence
T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessOne‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence
T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.